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Abstract 
It remains uncertain whether cystatin C is a superior marker of renal function than creatinine 
in older adults. We have investigated the association between estimated glomerular filtration 
rate (eGFR) using the Chronic Kidney Disease Epidemiology (CKD-EPI) equations based on 
creatinine (CKD-EPIcr) and cystatin C (CKD-EPIcys), and cardiovascular risk markers and 
mortality in older adults.  
Methods 
Cross sectional and prospective study of 1639 British men aged 71-92 years, followed up for 
an average 5 years for mortality. Cox’s survival model and receiving operating characteristic 
(ROC) analysis were used to assess the associations. 
Results 
The prevalence of CKD was similar using the two CKD-EPI equation although cystatin C 
reclassified 43.9% of those with stage 3a CKD (eGFR 45-59ml/min/1.732, moderate 
damage) to no CKD. However, CKD stages assessed using both CKD-EPIcr and CKD-
EPIcys were significantly associated with vascular risk markers and with all-cause and CVD 
mortality. In all men with CKD (eGFR < 60ml/min/1.732), the hazard ratio (HR) (95% 
confidence interval) for all-cause mortality after adjustment for cardiovascular risk factors 
compared to those with no CKD were 1.53 (1.20, 1.96) and 1.74 (1.35, 2.23) using CKD-
EPIcr and CKD-EPIcys respectively. Comparisons of the two CKD equations showed no 
significant difference in their predictive ability for mortality (difference in AUC p = 0.46). 
Conclusion 
Despite reclassification of CKD stages, assessment of CKD using CKD-EPIcys did not 
improve prediction of mortality in older British men >70 years. Our data does not support the 
routine use of CKD-EPIcys for identifying CKD in the elderly British male population. 
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Summary Box 
What is already known on this subject? 
Chronic kidney disease (CKD) is a significant worldwide public health problem associated 
with excess mortality and morbidity. CKD diagnosis relies on the estimated glomerular 
filtration rate (eGFR), traditionally based on equations using serum creatinine levels. It 
remains uncertain whether cystatin C is a superior marker of renal function than creatinine in 
older adults. We therefore investigated the association between estimated glomerular 
filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology (CKD-EPI) 
equations based on creatinine (CKD-EPIcr) and cystatin C (CKD-EPIcys), and 
cardiovascular risk markers and mortality in older adults. 
What does this study add? 
We found that the prevalence of CKD (eGFR < 60 ml/min/1.732) was similar irrespective of 
CKD equation used although cystatin C reclassified a large proportion of men with stage 3 
CKD (eGFR  30-59 ml/ min/1.732) based on creatinine to no CKD and these men did not 
show increased mortality risk. However, CKD stages assessed using both equations were 
significantly associated with vascular risk markers (inflammation, endothelial and cardiac 
dysfunction) and with all-cause and cardiovascular mortality. Comparisons of the two CKD 
equations showed no significant difference in their predictive ability for mortality. Despite 
reclassification of CKD stages, assessment of CKD using CKD-EPIcys did not improve 
prediction of mortality in white British men older than 70 years. Our data does not support 
the routine use of CKD-EPIcys for identifying CKD in the elderly British white male 
population.  
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Introduction 
Chronic kidney disease (CKD) is a significant worldwide public health problem associated with 
excess mortality and morbidity [1, 2]. CKD diagnosis relies on the estimated glomerular 
filtration rate (eGFR), traditionally based on equations using serum creatinine levels. Whilst 
the Modification of Diet in Renal Disease (MDRD) equation had been used for many years, 
more recent evidence suggests the CKD Epidemiology Collaboration (CKD-EPI) creatinine 
equation performs better in predicting mortality [3, 4]. 
Many population studies have shown the prevalence of CKD increases with increasing age 
[5]. Using creatinine in the older population to calculate eGFR may lead to an overestimation 
of the GFR as serum creatinine is influenced by muscle mass and dietary protein intake, both 
of which reduce with increasing age [6]. In view of the high prevalence of CKD in older adults 
and the growing ageing population, there is a need for measures of eGFR which can more 
accurately predict death in this population. Cystatin C is an alternative GFR marker less 
influenced by exogenous factors [6]. The National Institute for Health and Care Excellence 
(NICE) guidelines for the diagnosis of CKD in those with CKD Stage 3a (eGFR 45-
59ml/min/1.73m2) and no proteinuria recommends the use of cystatin C based equations to 
calculate eGFR [7]. 
There is conflicting evidence in the literature regarding the use of CKD-EPI cystatin C (CKD-
EPIcys) over CKD-EPI creatinine (CKD-EPIcr) based equations in the elderly population [8-
11]. Whilst a recent meta-analysis of sixteen studies has shown use of the CKD-EPIcys 
equation strengthens the association between the eGFR and the risks of death and end-stage 
renal disease, the majority of those included were younger individuals [12]. There is some 
evidence to suggest that there is no benefit in using the CKD-EPIcys equation in the elderly 
population [8, 9].  
Moreover, advanced CKD is associated with excess cardiovascular morbidity and mortality [1, 
2] and whether eGFR calculated using CKD-EPIcys equations are better indicators of CVD 
risk than CKD-EPIcr has been less studied. Therefore, to address these issues we have 1) 
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compared the predictive value of CKD-EPIcr and the CKD-EPIcys equations for all-cause and 
CVD mortality; 2) compared mortality by stages of CKD and 3) examined the association 
between these CKD-EPI equations with cardiovascular risk markers including arterial stiffness 
and cardiac markers in a cohort of older men in primary care. 
 
Methods 
The British Regional Heart Study is a prospective study which recruited a socioeconomically 
and geographically representative cohort of 7735 men from 24 British towns between 1978 
and 1980. This present study is an analysis of the data from the 2010-2012 re-examination 
when all surviving men (n = 3137), aged between 71–92 years, were sent a postal 
questionnaire and invited for a 30th year re-examination with the men being followed up until 
June 2016. The population studied was socio-economically representative and comprised 
predominantly white Europeans (>99%). 2137 (68%) men completed the postal questionnaire 
and 1722 (55%) men attended the re-examination [13]. Blood samples were collected after 
fasting for a minimum of six hours and were stored at −70°C. The National Research Ethics 
Service (NRES) Committee London provided ethical approval for the data collection. All men 
provided written informed consent to the investigations, which were carried out in accordance 
with the Declaration of Helsinki. The presence of co-morbidity was based on the men self-
reporting a doctor made diagnosis.  
 
CVD risk factors 
Physical examination included blood pressure (BP), height and weight, from which body mass 
index (BMI) was calculated [14]. Details of measurement and classification for smoking status 
and physical activity in this cohort have been previously described [15]. The use of 
antihypertensive medication was based on self-reported medication history. Measurements of 
metabolic, inflammatory and endothelial markers were taken as described previously [14, 16, 
6 
 
17]. C-reactive protein (CRP) (marker of inflammation) was assayed by ultra sensitive 
nephelometry (Dade Behring, Milton Keynes, UK). Interleukin-6 was assayed using a high-
sensitivity ELISA (R & D Systems, Oxford, UK). NT-pro brain natriuretic peptide (BNP) and 
cardiac troponin T (cTnT) were measured using the Elecsys 2010 electrochemiluminescence 
method (Roche Diagnostics, Burgess Hill, UK). Prevalent diabetes included men with doctor-
diagnosed diabetes and men with fasting blood glucose ≥7 mmol/L. Femoral PWV was 
assessed by two vascular technicians as previously described [18, 19].  
 
CKD assessment 
1639 men had at least one renal function blood measurement (83 missing). Cystatin C was 
measured using an automated method on a biochemistry analyser (c311, Roche Diagnostics, 
Burgess Hill, UK) and was calibrated and quality controlled using the manufacturers reagents. 
Creatinine was measured using an automated analyser and GFR was estimated using the 
CKD-EPIcr [20] and CKD-EPIcys [21] equations: 
CKD EPI creatinine =  141 × min (
creatinine
0.9
, 1)
−0.411
× max (
creatinine
0.9
, 1)
−1.209
× 0.993age 
where “min” indicated the minimum of creatinine/0.9 or 1 and “max” indicates the maximum of 
creatinine/0.9 or 1. 
CKD EPI cystatin C = 133 × min (
cystatin C
0.8
, 1)
−0.499
× max (
cystatin C
0.8
, 1)
−1.328
× 0.996age 
where “min” indicated the minimum of cystatin C/0.8 or 1 and “max” indicates the maximum of 
cystatin C/0.8 or 1. 
Estimated GFR is expressed in millilitres per min per 1.73 meters squared, weight in 
kilograms, age in years, cystatin C and creatinine in milligrams per decilitre. The men were 
initially classified into 6 CKD stages 1, 2, 3a, 3b, 4 and 5. Stage 1 and 2 indicates normal or 
mild CKD. Patients with CKD stage 3 had moderate CKD, stage 4 represents severe CKD and 
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stage 5 indicates kidney failure. In subsequent analyses three categories were defined: those 
with eGFR ≥ 60ml/min/1.732 (CKD stages 1 and 2), eGFR ≥ 30 and < 60ml/min/1.732 (CKD 
stages 3a [eGFR 45-59ml/min/1.732] and 3b [eGFR 30-44ml/min/1.732]), eGFR < 
30ml/min/1.732 (CKD stages 4 and 5). Of the 1639 men, 3 men had missing data on creatinine 
and 35 men had missing data on cystatin C. 
 
Mortality follow-up 
All men were followed prospectively for CVD and all-cause mortality from re-examination 
(2010-2012). In the present analyses, total mortality events are based on follow-up from re-
screening in 2010-2012 to 30th June 2016, a mean follow-up period of 5 years. Information 
on death was collected through the established “tagging” procedures provided by the National 
Health Service central registers. In order to obtain death notifications, details were supplied to 
the centre which enabled them to identify and tag the relevant cases [22]. Cardiovascular 
deaths included all those with International Classification of Diseases (ICD-9th Revision) 
codes 390–459.  
 
Statistical analysis 
Distributions of HbA1c, glucose, insulin, C-reactive protein (CRP), interleukin 6 (IL-6), NT-pro 
BNP and cTnT were highly skewed and log transformation was used. Comparisons of baseline 
characteristics between the CKD groups were carried out using the chi squared test for 
categorical variables and analysis of variance for continuous variables. 
Cox proportional hazards models were used to assess hazard ratios (HRs) for the three CKD 
definitions compared to subjects without CKD (i.e. stages 1 and 2) at baseline with respect to 
cardiovascular and all-cause mortality during follow up. Receiving operating characteristic 
(ROC) analysis was used to compare the predictive ability of the two equations. We also 
evaluated how all-cause mortality for each eGFR category changed depending on the 
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equation used. The ability of the CKD-EPIcys equation to reclassify mortality risk was 
assessed using methods suggested by Pencina et al. [23] by calculating the net 
reclassification improvement (NRI). All analyses were performed using SAS version 9.3 (SAS, 
Cary, North Carolina).  
 
Results 
This study was based on 1639 men aged 72-91 years who attended the 2010-2012 re-
examination and who had at least one renal blood measurement. Of these 1601 men had both 
renal blood measurements. Table 1 shows the prevalence of CKD stages using the CKD-
EPIcr and the reclassification of CKD stages when using CKD-EPIcys in comparison to CKD-
EPIcr. 32% were classified as having CKD using the creatinine based equation compared to 
32.4% using the cystatin C based equation. The CKD-EPIcys reclassified 15.9% of men with 
no CKD (stages 1 and 2) using the CKD-EPIcr to having CKD and 32.4% of those with CKD 
(eGFR < 60ml/min/1.732) to no CKD. The largest reclassification was seen in men with CKD 
stage 3a; use of CKD-EPIcys resulted in the reclassification of 43.9% of those with CKD stage 
3a to CKD stages 1 and 2 (i.e. no CKD) and 17.5% to a more advanced CKD stage. 
 
Cohort characteristics 
Men with no CKD, regardless of which equation was used, were the youngest and had the 
lowest prevalence of diabetes, inactivity, manual workers, use of anti-hypertensives, 
myocardial infarction (MI), heart failure (HF), and stroke (Table 2).  
 
Vascular risk markers and subclinical atherosclerosis 
Table 3 shows the association between CKD stages and age adjusted mean levels of 
cardiovascular risk markers. Both CKD-EPIcr and CKD-EPIcys showed significant 
associations with systolic blood pressure, HDL-C, inflammation, vWF, and cardiac markers 
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(NT-proBNP and cTnT). Only CKD-EPIcr was associated with mean levels of insulin and 
triglycerides. No association was seen with arterial stiffness.  
 
Mortality 
During a median follow-up time of 5 years, 300 of the 1639 men died. Of these, 99 men 
(33.0%) died of a cardiovascular cause. Table 4 shows the hazard ratio (HR) for all-cause and 
CVD mortality for the three main CKD stages (stages 1+2, 3a+3b and 4+5). In the age adjusted 
analysis, irrespective of CKD equations those with CKD stages 3, 4 and 5 showed significantly 
higher risk of all-cause and CVD mortality. Adjustment for major CVD risk factors (Table 4) 
slightly attenuated the association but the relationships with all-cause and CVD mortality 
remained significant. In particular, those classified as stage 3 CKD irrespective of CKD 
equations showed significantly higher risk of CVD and all-cause mortality even after 
adjustment than those with no CKD. Comparisons of ROC-AUC for the two CKD equations 
showed no significant difference in their predictive ability for mortality. In the multivariate 
analysis the AUC for CKD-EPIcr vs CKD-EPIcys were 0.733 (0.029) vs 0.737 (0.029) (p = 
0.46 for difference) for all-cause mortality and AUC = 0.746 (0.028) vs 0.754 (0.029) (p = 0.22 
for difference) for CVD mortality. 
 
We also examined the association between the two CKD equations and all-cause mortality 
separately in men with and without prevalent CVD or diabetes adjusting for major CVD risk 
factors. The associations were seen in both groups. In men with no prevalent CVD or diabetes 
(n = 1080), compared to those with no CKD, those with any CKD (stages 3, 4 or 5) had an 
adjusted HR (95% CI) of 1.39 (1.02, 1.89) and 1.50 (1.09, 2.05) using CKD-EPIcr and CKD-
EPIcys respectively. In the subset of participants with CVD or diabetes (n = 559), the 
corresponding HRs were 1.81 (1.19, 2.75) and 1.99 (1.30, 3.04) respectively.  
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We also examined the all-cause mortality risk in those categorised as any CKD (stages 
3a+3b+4+5) and no CKD based on the EPIcr and EPIcys equation and 4 groups were used: 
No CKD (both equations; n = 916) (reference group), CKD (using CKD-EPIcr only; n = 166), 
CKD (using CKD-EPIcys only; n = 173) and those classified as CKD for both equations (n = 
346). In multivariate analyses those with CKD based on creatinine who were reclassified 
downwards on the basis of cystatin C showed similar risk to those with no CKD. Those who 
were reclassified as CKD on the basis of cystatin C showed higher risk than those with no 
CKD but this difference was not significant. The HR for the four groups were 1.00, 1.03 (0.66, 
1.59), 1.31 (0.89, 1.92) and 1.99 (1.48, 2.67) respectively. 
 
Finally, we assessed the NRI for all-cause mortality using the CKD-EPIcys equation for the 
three CKD-EPIcr CKD categories (1+2, 3a+3b and 4+5). The reclassification of men who died 
and who did not die is shown in Table 5. Among men who died 49 men (16.8%) were 
reclassified to a higher CKD stage using the CKD-EPIcys equation and 28 men (9.6%) were 
reclassified to a lower CKD stage with the CKD-EPIcys equation. The net gain in 
reclassification in those who died was 0.087 (p < 0.01). Among men who did not die 77% were 
classified as the same CKD stage (149 were reclassified up and 144 were reclassified down). 
The net gain in those who did not die (NRI = 0.004) was not significant. The overall NRI was 
0.07 (p = 0.02). 
 
Discussion 
Our study has shown that in a representative sample of British men aged 71–92 years drawn 
from primary care, use of the CKD-EPIcys equation to calculate eGFR resulted in a similar 
prevalence of CKD compared to the CKD-EPIcr equation. However, cystatin C reclassified, in 
particular, a large proportion of those with CKD stage 3 to no CKD and these men showed 
similar risk to those with no CKD. However, the majority of men classified as having no CKD 
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using the creatinine based equation were also classified as having no CKD using the cystatin 
C based equation. Both equations predicted all-cause and CVD mortality and overall CKD-
EPIcys was not a significantly better predictor of all-cause or CVD mortality than CKD-EPIcr 
as measured by the AUC. The overall net reclassification improvement for total mortality 
although statistically significant was largely due to the events component. No improvement 
was seen for the non-events component. A recent study reported that use of eGFR calculated 
using CKD-EPIcys did not improve prediction of mortality in older men with CKD stage 3a in 
primary care [8]. This study only looked at participants with CKD stage 3; however, they were 
followed up, similar to our study, for 5 years. Survival models in this study were adjusted for 
age, sex, previous CVD as well as urine albumin-to-creatinine ratio, haemoglobin, albumin 
and bicarbonate which differed from our study. Our study extends the findings of Shardlow et 
al.  to a general older population with and without CKD in primary care. We also investigated 
the association between CKD (assessed using the CKD-EPIcys and CKD-EPIcr equations) 
and a wide range of metabolic, cardiac, inflammatory and non-invasive markers of arterial 
disease not previously reported. 
 
CKD and vascular risk 
Our findings confirm the known association between CKD and vascular risk factors including 
blood pressure, lipids, cardiac markers (NT-proBNP, cTnT) and inflammation [24-29]. With the 
exception of insulin, glucose and triglycerides both measures of eGFR showed significant 
associations with vascular risk markers. However, only, the CKD-EPIcr equation showed 
significant association with insulin. In contrast we found no association between CKD and 
arterial stiffness which is consistent with previous reports [30]. Overall both equations showed 
significant associations with most of the major vascular risk markers. 
 
CKD and mortality 
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In this study of older men, the use of CKD-EPIcys did not improve the prediction of mortality 
in the general elderly male cohort overall as measured by the AUC. The findings indicate that 
the use of CKD-EPIcr is sufficient as an initial screening tool. Only 16% of men were 
reclassified as having CKD on the basis of cystatin C and these men showed a slightly higher 
mortality risk than those with no CKD but the difference was not significant. The non-significant 
findings may be due to the small numbers in the study and larger studies are needed to confirm 
this. However, our findings that those classified as having CKD on the basis of creatinine but 
not on cystatin C based equation did not show higher risk than those with no CKD supports 
NICE guidelines in the use of cystatin C in those with CKD stage 3a to rule out CKD [7]. 
Few studies have compared the association between CKD-EPIcr and CKD-EPIcys based 
equations with mortality in the general older adult population and the findings have been 
inconsistent. Our findings confirm previous reports from a prospective cohort study of 1165 
elderly women aged over 70 years in Western Australia followed up for 10 years which found 
the CKD-EPIcys equation was not superior in predicting all-cause mortality or CVD events 
compared to the CKD-EPIcr equation [9]. In this study, similarly to ours, the findings were 
adjusted for age, BMI, smoking history, diabetes, systolic blood pressure, use of 
antihypertensive medications, prevalent renal disease and CVD. Our adjustments also 
included cholesterol and prevalent heart failure. 
By contrast one study has found CKD-EPIcr is associated with a U-shaped increased HR of 
mortality with both high and low eGFR being associated with increased mortality whilst using 
the CKD-EPIcys equation showed a linear association between eGFR and all-cause mortality 
[31]. Of note, participants in this study had a mean age of 85 years, which is older than our 
cohort and had a shorter follow up of 2.6 years. A further study looking at 2994 community 
dwelling men with a mean age of 76.4 years showed that the CKD-EPIcr equation was inferior 
to the CKD-EPIcys equation in predicting all-cause mortality [10]. The reasons for the 
differences in findings are not clear but this study included a multi-ethnic population who were 
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on average slightly younger and included men under 70 years of age and had a longer follow 
up time of 7.3 years compared to 5 years in our study. 
 
Strengths and limitations 
The strengths of our study include the fact that it is a study of older men, a group who are at 
high risk of CKD and vascular disease and a group in whom there has been limited evidence 
for the validity of cystatin C based eGFR equations. However, the BRHS includes a 
predominantly older white male population of European extraction. This limits generalisability 
to women, middle-aged adults and ethnic minority groups. The response rate for the baseline 
assessment in this study was 55%, and, therefore, the issue of survival bias cannot be 
overlooked. Although men who participated in our re-examination study were healthier 
(younger, more active, lower BMI, less disabled, lower prevalence of CVD and diabetes) at 
the previous examination 10 years earlier than those who did not, there was little difference in 
prevalence of CKD between responders and non-responders. Although healthy survival bias 
may underestimate the prevalence of CKD in older adults and the incident mortality rates may 
be lower than the total population, this should not bias the nature of the association between 
CKD and mortality. Moreover, we have shown that the two equations showed broadly similar 
significant associations with mortality in men with and without CVD or diabetes. Whilst we 
have focused on CKD in this study, acute kidney injury (AKI, i.e. a rapid decline in GFR), is an 
important clinical problem encountered on a day-to-day basis. Studies have shown that 
compared to creatinine, cystatin C is an earlier marker of AKI which we have not discussed in 
this paper [6]. In the elderly, using a cystatin C based equation has been shown to estimate 
larger declines in kidney function than a creatinine based equation [32]. We have used single 
measures of creatinine and cystatin C to calculate eGFR and we have not looked at changes 
in eGFR or compared this to the gold standard measured GFR as these data were not 
available. Another potential limitation was the lack of albuminuria measurement in this cohort. 
 
14 
 
Conclusion 
Estimating GFR using CKD-EPIcys leads to a similar prevalence of CKD compared to CKD-
EPIcr although a large proportion of stage 3a CKD were reclassified as having no CKD. 
Assessment of CKD using CKD-EPIcys does not significantly improve prediction of all-cause 
and CVD mortality in older white British men when compared to CKD-EPIcr. Both CKD 
equations showed similar associations with inflammatory and cardiac risk markers and 
markers of subclinical atherosclerosis. Creatinine measurement is inexpensive and widely 
available. Data from our study supports the use of CKD-EPIcr as an initial screening tool for 
the assessment of eGFR at least in older white British men although the CKD-EPIcys equation 
may be useful in reclassifying those with CKD stage 3a. 
 
Contributions 
SGW initiated the concept and design of the paper. SZ analysed the data with help from OP 
and drafted the manuscript. SGW, JPJH, EAE, PHW contributed to the interpretation of 
data.  EAE, JPJH, LL, PHW and SGW contributed to the acquisition of the data. All authors 
assessed the manuscript critically for important intellectual content and approved the final 
version. 
 
Funding 
The British Regional Heart Study is a British Heart Foundation (BHF) research group. This 
work was supported by a British Heart Foundation programme grant (RG/13/16/30528) and 
project grant (PG/09/024).  
 
Competing Interests 
The authors report no conflicts of interest. 
15 
 
 
Exclusive Licence  
The Corresponding Author has the right to grant on behalf of all authors and does grant on 
behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a 
worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if 
accepted) to be published in JECH editions and any other BMJPGL products to exploit all 
subsidiary rights, as set out in our licence.  
(http://group.bmj.com/products/journals/instructions-for-authors/licence-forms/). 
 
Ethics statement 
The National Research Ethics Service (NRES) Committee London provided ethical approval 
for the data collection. All men provided written informed consent to the investigations, which 
were carried out in accordance with the Declaration of Helsinki.   
16 
 
References 
1. Gansevoort, R.T., Correa-Rotter, R., Hemmelgarn, B.R. et al., Chronic kidney 
disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet, 
2013. 382(9889): p. 339-52. 
2. Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C.Y. Chronic kidney 
disease and the risks of death, cardiovascular events, and hospitalization. N Engl J 
Med, 2004. 351(13): p. 1296-305. 
3. Matsushita, K., Tonelli, M., Lloyd, A. et al., Clinical risk implications of the CKD 
Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of 
Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis, 
2012. 60(2): p. 241-9. 
4. Stevens, L.A., Li, S., Kurella Tamura, M. et al., Comparison of the CKD Epidemiology 
Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study 
equations: risk factors for and complications of CKD and mortality in the Kidney Early 
Evaluation Program (KEEP). Am J Kidney Dis, 2011. 57(3 Suppl 2): p. S9-16. 
5. Coresh, J., Selvin, E., Stevens, L.A. et al., Prevalence of chronic kidney disease in 
the United States. JAMA, 2007. 298(17): p. 2038-47. 
6. Lassus, J. and V.-P. Harjola, Cystatin C: a step forward in assessing kidney function 
and cardiovascular risk. Heart Failure Reviews, 2012. 17(2): p. 251-261. 
7. National Institute for Clinical Excellence. Chronic kidney disease in adults: 
assessment and management. 2015; Available from: 
https://www.nice.org.uk/guidance/cg182/chapter/1-recommendations. 
8. Shardlow, A., McIntyre, N.J., Fraser, S.D.S. et al., The clinical utility and cost impact 
of cystatin C measurement in the diagnosis and management of chronic kidney 
disease: A primary care cohort study. PLOS Medicine, 2017. 14(10): p. e1002400. 
9. Lim, W.H., Lewis, J.R., Wong, G. et al., Comparison of estimated glomerular filtration 
rate by the chronic kidney disease epidemiology collaboration (CKD-EPI) equations 
with and without Cystatin C for predicting clinical outcomes in elderly women. PLoS 
One, 2014. 9(9):p. e106734. 
10. Canales, M.T., Blackwell, T., Ishani, A. et al., Estimated GFR and Mortality in Older 
Men: Are All eGFR Formulae Equal? American journal of nephrology, 2016. 43(5): p. 
325-333. 
11. Zhu, Y., Ye, X., Zhu, B. et al., Comparisons between the 2012 new CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) equations and other four 
approved equations. PLoS One, 2014. 9(1): p. e84688. 
12. Shlipak, M.G., Matsushita, K., Ärnlöv, J. et al., Cystatin C versus Creatinine in 
Determining Risk Based on Kidney Function. New England Journal of Medicine, 
2013. 369(10): p. 932-943. 
13. Lennon, L.T., Ramsay, S.E., Papacosta, O., Shaper, A.G., Wannamethee, S.G., 
Whincup, P.H.. Cohort Profile Update: The British Regional Heart Study 1978-2014: 
35 years follow-up of cardiovascular disease and ageing. Int J Epidemiol, 2015. 
44(3): p. 826-826g. 
14. Ramsay, S.E., Arianayagam, D.S., Whincup, P.H. et al., Cardiovascular risk profile 
and frailty in a population-based study of older British men. Heart, 2015. 101(8): p. 
616-22. 
15. Wannamethee, S.G., Lowe, G.D., Whincup, P.H., Rumley, A., Walker, M., Lennon, L. 
Physical activity and hemostatic and inflammatory variables in elderly men. 
Circulation, 2002. 105(15): p. 1785-90. 
17 
 
16. Wannamethee, S.G., Whincup, P.H., Shaper, A.G., Rumley, A., Lennon, L., Lowe, 
G.D. Circulating inflammatory and hemostatic biomarkers are associated with risk of 
myocardial infarction and coronary death, but not angina pectoris, in older men. 
Journal of Thrombosis and Haemostasis, 2009. 7(10): p. 1605-1611. 
17. Wannamethee, G.S., Welsh, P., Whincup, P.H., Lennon, L., Papacosta, O., Sattar, 
N. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of 
heart failure over other routine clinical risk parameters in older men with and without 
cardiovascular disease: population-based study. European Journal of Heart Failure, 
2014. 16(1): p. 25-32. 
18. Parsons, T.J., Sartini, C., Ellins, E.A. et al., Objectively measured physical activity 
and sedentary behaviour and ankle brachial index: Cross-sectional and longitudinal 
associations in older men. Atherosclerosis, 2016. 247: p. 28-34. 
19. Zonoozi, S., Ramsay, S.E., Papacosta, O. et al., Self-reported sleep duration and 
napping, cardiac risk factors and markers of subclinical vascular disease: cross-
sectional study in older men. BMJ Open, 2017. 7(6). 
20. Levey, A.S., Stevens, L.A., Schmid, C.H. et al., A new equation to estimate 
glomerular filtration rate. Ann Intern Med, 2009. 150(9): p. 604-12. 
21. Inker, L.A., Schmid, C.H., Tighiouart, H. et al., Estimating glomerular filtration rate 
from serum creatinine and cystatin C. N Engl J Med, 2012. 367(1): p. 20-9. 
22. Walker, M., Shaper, A.G., Lennon, L., Whincup, P. H.  Twenty year follow-up of a 
cohort based in general practices in 24 British towns. J Public health Medicine 
2000;22:479-485. 
23. Pencina, M.J., D'Agostino, R.B Sr., D'Agostino, R.B Jr., Vasan, R.S. Evaluating the 
added predictive ability of a new marker: From area under the ROC curve to 
reclassification and beyond. Statistics in Medicine, 2008. 27(2): p. 157-172. 
24. Zheng, W., Qian, G., Hao, W. et al., Cardiovascular metabolic risk factors and 
glomerular filtration rate: a rural Chinese population study. Lipids in Health and 
Disease, 2016. 15: p. 180. 
25. Kang, S.H., Jung, D.J., Choi, E.W., Cho, K.H., Park, J.W., Do, J.Y. HbA1c Levels Are 
Associated with Chronic Kidney Disease in a Non-Diabetic Adult Population: A 
Nationwide Survey (KNHANES 2011–2013). PLoS ONE, 2015. 10(12): p. e0145827. 
26. Abbas, N.A., John, R.I., Webb, M.C., et al., Cardiac Troponins and Renal Function in 
Nondialysis Patients with Chronic Kidney Disease. Clinical Chemistry, 2005. 51(11): 
p. 2059-2066. 
27. Chung, J.Z.Y. and G.R.D. Jones, Effect of renal function on serum cardiac troponin T 
— Population and individual effects. Clinical Biochemistry, 2015. 48(12): p. 807-810. 
28. Gupta, J., Mitra, N., Kanetsky, P.A. et al., Association between Albuminuria, Kidney 
Function, and Inflammatory Biomarker Profile in CKD in CRIC. Clinical Journal of the 
American Society of Nephrology: CJASN, 2012. 7(12): p. 1938-1946. 
29. Shankar, A., Sun, L., Klein, B.E. et al., Markers of inflammation predict the long-term 
risk of developing chronic kidney disease: a population-based cohort study. Kidney 
International, 2011. 80(11): p. 1231-1238. 
30. Sathi, S., Mahapatra, H., Sunder, S. et al., Nontraditional Cardiovascular Biomarkers 
and Estimation of Cardiovascular Risk in Predialysis Chronic Kidney Disease 
Patients and Their Correlations With Carotid Intima Media Thickness. Nephro-
urology Monthly, 2014. 6(6): p. e22112. 
31. Shastri, S., Katz, R., Rifkin, D.E. et al., Kidney Function and Mortality in 
Octogenarians: Cardiovascular Health Study All Stars. Journal of the American 
Geriatrics Society, 2012. 60(7): p. 1201-1207. 
18 
 
32. Shlipak, M.G., Katz, R., Kestenbaum, B. et al., Rate of Kidney Function Decline in 
Older Adults: A Comparison Using Creatinine and Cystatin C. American Journal of 
Nephrology, 2009. 30(3): p. 171-178.  
19 
 
Table 1. Reclassification of CKD stages using CKD-EPIcys in comparison to CKD-EPIcr 
CKD 
stages 
CKD-EPIcys  Total 
(% of all men) 1 2 3a 3b 4 5  
CKD-
EPIcr 
1 29 (90.6%) 3 (9.4%) 0 0 0 0 100% 32 (2.0%) 
2 348 (32.9%) 536 (50.7%) 156 (14. 8%) 16 (1.5%) 1 (0.1%) 0 100% 1057 (66.0%) 
3a 31 (9.2%) 117 (34.7%) 130 (38.6%) 57 (16.9%) 2 (0.6%) 0 100% 337 (21.0%) 
3b 3 (2.0%) 15 (10.1%) 35 (23.5%) 73 (49.0%) 23 (15.4%) 0 100% 149 (9.3%) 
4 0 0 1 (4.2%) 5 (20.8%) 17 (70.8%) 1 (4.2%) 100% 24 (1.5%) 
5 0 0 0 0 1 (50%) 1 (50%) 100% 2 (0.12%) 
Total (% of 
all men) 
411 (25.7%) 671 (41.9%) 322 (20.1%) 151 (9.4%) 44 (2.8%) 2 (0.1) 
 
1601 
CKD, chronic kidney disease 
 
CKD stage 1 – eGFR > 90ml/min/1.732; CKD stage 2 - eGFR 60-90ml/min/1.732; CKD stage 3a - 
eGFR 45-59ml/min/1.732; CKD stage 3b - eGFR 30-44ml/min/1.732; CKD stage 4 - eGFR 15-
29ml/min/1.732; CKD stage 5 – eGFR < 15ml/min/1.732 
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Table 2. Baseline characteristics according to CKD categories by CKD-EPI equations 
 
  
CKD-EPI Cr 
p 
CKD-EPI Cys 
p 
  
1 + 2 
n = 1112a 
3a + 3b  
n = 497a 
4 + 5  
n = 27a 
1 + 2 
n = 1084a  
3a + 3b 
n = 474a  
4 + 5  
n = 46a 
Age Mean±std 77.5 ± 4.2 80.3 ± 5 79.1 ± 4.8 <.0001 77.5 ± 4.2 80.31 ± 5 79.4 ± 5 <0.0001 
Obese % 19.1 19.2 26.9 0.60 18.9 18.1 31.84 0.08 
Smoker % 3.1 4.5 3.9 0.38 2.5 4.9 11.1 0.001 
Inactive % 34.0 47.3 55.6 <0.0001 33.1 47.5 63.0 <0.0001 
Manual Social 
Class 
% 42.6 49.7 55.6 0.04 43.2 48.8 52.1 0.09 
Diabetes % 15.0 19.3 25.9 0.04 15.6 18.2 21.7 0.28 
Using 
Antihypertensives 
% 48.8 64.0 66.8 <0.0001 47.7 65.0 73.0 <0.0001 
MI % 12.8 20.4 30.4 0.0002 13.0 19.2 31.6 0.0002 
HF % 1.2 4.4 15.8 <0.0001 1.1 4.1 18.2 <0.0001 
Stroke % 8.0 15.2 8.0 <.00001 8.2 14.7 9.5 0.0006 
Table 2. Cohort demographics 
a, maximum n in group, varies slightly with missing co-variate data 
MI, myocardial infarction; HF, heart failure; PVD, peripheral vascular disease 
CKD stage 1 – eGFR > 90ml/min/1.732; CKD stage 2 - eGFR 60-90ml/min/1.732; CKD stage 3a - 
eGFR 45-59ml/min/1.732; CKD stage 3b - eGFR 30-44ml/min/1.732; CKD stage 4 - eGFR 15-
29ml/min/1.732; CKD stage 5 – eGFR < 15ml/min/1.732 
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Table 3. Association between CKD stages assessed using cystatin C vs creatinine and metabolic risk factors, inflammatory and endothelial markers, cardiac 
markers and non-invasive vascular measurements 
  CKD-EPIcr 
p 
CKD-EPIcys 
p 
  
1 + 2 
n = 1112b 
3a + 3b 
n = 497b 
4 + 5 
n = 27b 
1 + 2 
n = 1084b 
3a + 3b 
n = 474b 
4 + 5 
n = 46b 
Metabolic risk factors (age adjusted mean (95% CI)) 
SBP (mmHg) 147.8 (146.7, 149.0) 143.8 (142.1, 145.5) 138.5 (131.3, 145.8) <0.0001 148.1 (146.9, 149.2) 144.4 (142.6, 146.1) 132.2 (126.7, 137.8) <0.0001 
HDL-C 
(mmol/L) 
1.50 (1.47, 1.52) 1.36 (1.32, 1.40) 1.25 (1.10, 1.41) <0.0001 1.49 (1.47, 1.52) 1.39 (1.35, 1.43) 1.22 (1.09, 1.34) <0.0001 
Triglycerides 
(mmol/L) 
1.23 (1.19, 1.27) 1.43 (1.37, 1.49) 1.67 (1.44, 1.91) <0.0001 1.28 (1.24, 1.32) 1.31 (1.25, 1.37) 1.47 (1.28, 1.66) 0.08 
HbA1c (%) 5.79 (5.75, 5.8) 5.95 (5.89, 6.00) 6.13 (5.87, 6.39) <0.0001 5.81 (5.77, 5.75) 5.93 (5.53, 5.75) 5.96 (5.20, 5.82) 0.03 
Glucosea 
(mmol/L) 
5.61 (5.53, 5.70) 5.66 (5.53, 5.75) 5.80 (5.37, 6.30) 0.33 5.64 (5.53, 5.70) 5.66 (5.56, 5.78) 5.47 (5.23, 5.87) 0.55 
Insulina 
(Mu/L) 
7.78 (7.46, 8.08) 9.00 (8.50, 9.58) 9.00 (6.96, 11.59) 0.0004 7.39 (7.77, 8.33) 8.49 (8.00, 9.03) 7.39 (6.36, 9.30) 0.33 
Inflammatory and endothelial markers (age adjusted mean (95% CI)) 
CRPa (mg/L) 1.23 (1.15, 1.32) 1.64 (1.47, 1.84) 3.46 (2.18, 4.57) <0.0001 1.12 (1.04, 1.20) 1.95 (1.75, 2.18) 3.94 (2.80, 5.53) <0.0001 
IL-6a (pg/mL) 2.94 (2.83, 3.09) 3.32 (3.10, 3.56) 6.93 (5.23,9.51) <0.0001 2.80 (2.69, 2.92) 3.67 (3.42, 3.94) 6.55 (5.31, 8.08) <0.0001 
vWF (IU/dL) 130.4 (126.0, 134.7) 142.1 (135.7, 148.9) 181.0 (153.4, 208.6) <0.0001 126.9 (122.4, 131.3) 147.5 (140.8, 154.2) 179.2 (157.8, 200.7) <0.0001 
Cardiac markers (age adjusted mean (95% CI)) 
NT-pro BNPa 
(pg/mL) 
122.7 (114.4, 134.3) 177.7 (157.6, 200.5) 871.3 (523.2, 1480.3) <0.0001 115.6 (106.7, 125.21) 192.5 (170.7, 217.06) 828.8 (561.2, 1224.2) <0.0001 
cTnTa (pg/ml) 10.07 (9.68, 10.38) 13.32 (12.56, 14.15) 26.0 (20.49, 33.12) <0.0001 9.68 (9.30, 10.07) 14.15 (13.33, 14.88) 23.34 (19.49, 27.94) <0.0001 
Non-invasive vascular measurements  (age adjusted mean (95% CI)) 
PWV (m/s) 10.19 (10.09, 10.28) 10.11 (9.95, 10.26) 9.47 (8.82, 10.12) 0.09 10.15 (10.04, 10.25) 10.19 (10.03, 10.35) 9.60 (9.06, 10.14) 0.11 
a, geometric mean; b, maximum n in group, varies slightly with missing co-variate data 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; HbA1c, glycated haemoglobin; CRP, C-reactive 
protein; IL-6, interleukin 6; vWF, von Willebrand factor; FEV1, forced expiratory volume in 1s; NT-pro BNP, N-terminal pro brain natriuretic peptide; cTnT, 
cardiac troponin T;; PWV, pulse wave velocity;  
CKD stage 1 – eGFR > 90ml/min/1.732; CKD stage 2 - eGFR 60-90ml/min/1.732; CKD stage 3a - eGFR 45-59ml/min/1.732; CKD stage 3b - eGFR 30-
44ml/min/1.732; CKD stage 4 - eGFR 15-29ml/min/1.732; CKD stage 5 – eGFR < 15ml/min/1.732 
Missing data SBP (n=3); triglycerides (n=1); HDL-C (n=1); Hba1c (n=42); glucose (n=103); insulin (n=27); CRP (n=38); IL-6 (n=21); vWF (n=34); NTproBNP 
(n=37); cTnT (n=37); PWV (n=29) 
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Table 4. Hazard ratio for all-cause and CVD mortality according to CKD categories based on eGFR 
equations derived from serum creatinine (CKD-EPIcr) and from cystatin C (CKD-EPIcys)  
  Mortality Hazard Ratio (95% confidence interval) 
  All-Cause CVD 
  Age-adjusted Adjusted + Age-adjusted Adjusted + 
CKD-
EPIcr 
CKD 
Stages 
1+2 1 1 1 1 
3a+3b 1.60 (1.26, 2.05) 1.45 (1.13, 1.87) 2.02 (1.32, 3.11) 1.65 (1.05, 2.58) 
4+5 3.88 (2.23, 6.74) 3.51 (1.99, 6.17) 6.62 (2.94, 14.88) 4.72 (2.03, 11.01) 
 3a+3b+4+5 (CKD) 1.70 (1.34, 2.16) 1.53 (1.20, 1.96) 2.21 (1.46, 3.36) 1.77 (1.14, 2.75) 
CKD-
EPIcys 
CKD 
Stages 
1+2 1.00 1.00 1.00 1.00 
3a+3b 1.75 (1.36, 2.25) 1.66 (1.28, 2.15) 2.33 (1.48, 3.65) 2.01 (1.26, 3.20) 
4+5 3.63 (2.32, 5.68) 2.85 (1.75, 4.64) 6.45 (3.26, 12.78) 3.92 (1.82, 8.45) 
3a+3b+4+5 (CKD) 1.88 (1.48, 2.40) 1.74 (1.35, 2.23) 2.62 (1.70, 4.05) 2.13 (1.35, 3.37) 
CKD, chronic kidney disease 
CKD stage 1 – eGFR > 90ml/min/1.732; CKD stage 2 - eGFR 60-90ml/min/1.732; CKD stage 3a - 
eGFR 45-59ml/min/1.732; CKD stage 3b - eGFR 30-44ml/min/1.732; CKD stage 4 - eGFR 15-
29ml/min/1.732; CKD stage 5 – eGFR < 15ml/min/1.732 
+Adjusted for age, smoking, cholesterol, systolic blood pressure, BMI, prevalent diabetes, prevalent 
CVD (stroke, MI), prevalent heart failure, and BP lowering drugs.  
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Table 5. Reclasssification of men using the CKD-EPIcys equation among men who died and those 
who did not die on follow-up 
 
 CKD-EPI Cys   
 1+2 3a+3b 4+5 Total  
CKD-EPIcr Number of men who died (n = 291)  
1+2 110 
(75.3%) 
36 
(24.7%) 
0 146  
3a+3b 26 
(19.7%) 
93 
(70.5%) 
13 
(9.8%) 
132 49 classified up 
28 classified down 
4+5 0 
(0%) 
2 
(15.4%) 
11 
 (84.6%) 
13  
 NRI = 0.07 p = 0.01  
 
 Number of men who did not die (n = 1310)  
1+2 806 
(85.4%) 
136 
(14.4%) 
1 
 (0.1%) 
943 149 classified up 
144 classified down 
3a+3b 140 
(39.5%) 
202 
(57.1%) 
12 
(3.4%) 
354  
4+5 0  4 
(30.8%) 
9 
(69.2%) 
13  
 NRI = 0.004  p = 0.39  
Overall NRI = 0.068  p = 0.02  
CKD, chronic kidney disease; NRI, net reclassification improvement 
CKD stage 1 – eGFR > 90ml/min/1.732; CKD stage 2 - eGFR 60-90ml/min/1.732; CKD stage 3a - 
eGFR 45-59ml/min/1.732; CKD stage 3b - eGFR 30-44ml/min/1.732; CKD stage 4 - eGFR 15-
29ml/min/1.732; CKD stage 5 – eGFR < 15ml/min/1.732 
 
